Progress in Medicinal Chemistry, Volume 24Progress in Medicinal Chemistry |
Contents
29 | |
Biological Distribution and SubstrateInhibitor Specificity | 85 |
Chapter 4 Platinum Antitumour Agents | 129 |
Chapter 5 Towards Cannabinoid Drugs | 159 |
Chapter 6 Hypoglycaemic Agents Which Do Not Release Insulin | 209 |
Chapter 7 Calcium Channel Blocking Drugs | 249 |
Chapter 8 The Medicinal Chemistry of Aldose Reductase Inhibitors | 299 |
345 | |
353 | |
357 | |
Common terms and phrases
1,4-dihydropyridines Abstr Acta action adenylate cyclase administration affinity agents agonist aldehyde oxidase analgetic analogues animals antagonists antibodies antiemetic antitumour effects binding sites Biochem Biol Biophys calcium channel calcium channel blocking Cancer cannabinoids Cannabis Caº cardiac cells cerebral cortex chain channel blocking drugs Chem ciglitazone cisplatin Clin clinical complex compounds concentrations cooh cyclic AMP cyclic AMP accumulation decrease diabetic diltiazem dose enzyme fatty acid glucose guinea-pig brain H]mepyramine H]nitrendipine H1-antagonists Hi-receptor hypoglycaemic ICso value impromidine increase inhibition inhibitors inositol insulin interaction lens levels ligand liver Mechoulam membrane mepyramine metabolism mg/kg mice molybdenum hydroxylases nabilone Nature London nifedipine nitrendipine observed Olsnes oxidation Pharmacol plasma potent Proc produced protein rabbit receptor reduced response to histamine ricin rôle shown side-effects slices sorbitol specific stimulation structure studies substrate tested Ther tissue tolrestat toxicity toxin treatment tumour uptake verapamil vitro vivo xanthine oxidase